MEP26708A - Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method - Google Patents

Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method

Info

Publication number
MEP26708A
MEP26708A MEP-267/08A MEP26708A MEP26708A ME P26708 A MEP26708 A ME P26708A ME P26708 A MEP26708 A ME P26708A ME P26708 A MEP26708 A ME P26708A
Authority
ME
Montenegro
Prior art keywords
coating
preparation
compound
inert
pharmaceutical oral
Prior art date
Application number
MEP-267/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Darder Carlos Picornell
Original Assignee
Liconsa Liberacion Controlada De Sustancias Activas S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8304581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP26708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Liberacion Controlada De Sustancias Activas S A filed Critical Liconsa Liberacion Controlada De Sustancias Activas S A
Publication of MEP26708A publication Critical patent/MEP26708A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MEP-267/08A 1998-07-21 1999-07-20 Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method MEP26708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801539A ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
PCT/ES1999/000230 WO2000004881A1 (es) 1998-07-21 1999-07-20 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion

Publications (1)

Publication Number Publication Date
MEP26708A true MEP26708A (en) 2010-06-10

Family

ID=8304581

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-267/08A MEP26708A (en) 1998-07-21 1999-07-20 Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method

Country Status (30)

Country Link
US (1) US6737082B1 (et)
EP (1) EP1103252B1 (et)
JP (1) JP4190732B2 (et)
KR (1) KR100572135B1 (et)
AT (1) ATE234077T1 (et)
AU (1) AU750730B2 (et)
BG (1) BG65187B1 (et)
BR (1) BR9912300A (et)
CA (1) CA2337509C (et)
CZ (1) CZ291938B6 (et)
DE (1) DE69905905T2 (et)
DK (1) DK1103252T3 (et)
EE (1) EE04415B1 (et)
ES (2) ES2157731B1 (et)
HR (1) HRP20010128B1 (et)
HU (1) HU228895B1 (et)
IL (1) IL140910A (et)
ME (1) MEP26708A (et)
MX (1) MXPA01000681A (et)
NO (1) NO320054B1 (et)
NZ (1) NZ509886A (et)
PL (1) PL194740B1 (et)
PT (1) PT1103252E (et)
RS (1) RS50063B (et)
RU (1) RU2209628C2 (et)
SK (1) SK283279B6 (et)
TR (1) TR200100177T2 (et)
UA (1) UA64009C2 (et)
WO (1) WO2000004881A1 (et)
ZA (1) ZA200101293B (et)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1122456C (zh) * 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DK1438961T4 (da) * 2003-01-14 2014-11-17 Acino Pharma Ag Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
EP1438960B2 (en) * 2003-01-14 2012-12-19 Acino Pharma AG Compostion of itraconazole dispersed in a hydrophilic polymer having enhanced bioavailability
FR2852607B1 (fr) * 2003-03-20 2006-07-14 Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
WO2005011702A1 (en) * 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
CN101283984B (zh) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP2013521249A (ja) * 2010-03-05 2013-06-10 ビーエーエスエフ ソシエタス・ヨーロピア 融解物で被覆された医薬形態
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
JP2018520114A (ja) * 2015-05-25 2018-07-26 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． イソトレチノインの１日１回経口医薬組成物
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
EP3786231A4 (en) * 2018-04-27 2021-06-09 Toppan Printing Co., Ltd. DELAYED RELEASE COMPOSITE PARTICLES, METHOD FOR MANUFACTURING DELAYED RELEASE COMPOSITE PARTICLES, DRY POWDER AND WALLPAPER
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
EP4452232A1 (en) * 2021-12-22 2024-10-30 Palau Pharma, S.L.U. Multiparticulate albaconazole composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
CA2255663C (en) * 1996-05-24 2002-08-20 Schering Corporation Antifungal composition with enhanced bioavailability
CA2258683C (en) * 1996-06-28 2007-07-31 Schering Corporation Oral composition comprising a triazole antifungal compound
DE19626924C2 (de) * 1996-07-04 1999-08-19 Epazon B V Gerät zur Bereitstellung eines Atemgases
JP3608800B2 (ja) * 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤

Also Published As

Publication number Publication date
AU750730B2 (en) 2002-07-25
BG105282A (en) 2001-11-30
ES2194480T3 (es) 2003-11-16
NZ509886A (en) 2002-09-27
SK862001A3 (en) 2001-08-06
KR20010070990A (ko) 2001-07-28
JP2002521323A (ja) 2002-07-16
TR200100177T2 (tr) 2001-07-23
ES2157731A1 (es) 2001-08-16
IL140910A (en) 2004-03-28
EE04415B1 (et) 2005-02-15
NO20010289D0 (no) 2001-01-17
HRP20010128B1 (en) 2003-12-31
DE69905905T2 (de) 2004-03-04
KR100572135B1 (ko) 2006-04-19
JP4190732B2 (ja) 2008-12-03
RS50063B (sr) 2009-01-22
NO320054B1 (no) 2005-10-17
UA64009C2 (en) 2004-02-16
AU4782199A (en) 2000-02-14
CA2337509A1 (en) 2000-02-03
HRP20010128A2 (en) 2002-12-31
ES2157731B1 (es) 2002-05-01
DE69905905D1 (de) 2003-04-17
EP1103252A1 (en) 2001-05-30
ATE234077T1 (de) 2003-03-15
HUP0103708A2 (hu) 2002-02-28
HK1037531A1 (en) 2002-02-15
BG65187B1 (bg) 2007-06-29
PL345625A1 (en) 2002-01-02
NO20010289L (no) 2001-03-07
EE200100041A (et) 2002-06-17
YU3901A (sh) 2003-08-29
CZ291938B6 (cs) 2003-06-18
HUP0103708A3 (en) 2002-07-29
WO2000004881A1 (es) 2000-02-03
RU2209628C2 (ru) 2003-08-10
HU228895B1 (en) 2013-06-28
MXPA01000681A (es) 2002-04-24
EP1103252B1 (en) 2003-03-12
IL140910A0 (en) 2002-02-10
PT1103252E (pt) 2003-07-31
ZA200101293B (en) 2001-08-21
CZ2001175A3 (en) 2001-05-16
DK1103252T3 (da) 2003-07-14
PL194740B1 (pl) 2007-06-29
CA2337509C (en) 2005-12-27
BR9912300A (pt) 2001-04-17
SK283279B6 (sk) 2003-05-02
US6737082B1 (en) 2004-05-18

Similar Documents

Publication Publication Date Title
MEP26708A (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
EA200300999A1 (ru) Хронотерапевтические дозированные формы
DK1059848T3 (da) Dragéret tyggegummi, fremgangsmåde til fremstilling hraf samt anvendelse af et eller flere aktive stoffer i fast form
HRP20010463B1 (hr) Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
CA2044398A1 (en) Programmed release oral solid pharmaceutical dosage form
JP2003512395A5 (et)
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
ATE181206T1 (de) Synergetische termitizide zusammensetzung aus pyrethroid und n-phenyl-pyrazol
BG104193A (en) Peroral pharmaceutical preparation including a compound with antiulcerous activity, and method for its preparation
NZ515230A (en) Fast-dispersing dosage forms containing fish gelatin
DK1124539T3 (da) Farmaceutisk formulering der omfatter omeprazol
WO2005027843A3 (en) Chronotherapeutic dosage forms
RU2001104894A (ru) Пероральная фармацевтическая композиция на основе соединения, имеющего антигрибковую активность, и способ ее получения
NO20033305D0 (no) Nytt filmbelegg
EP1177788A3 (en) Pharmaceutical composition of fluoxetin in coated dispersible tablets and process for its manufacture
ES2108619A1 (es) Composicion insecticida/acaricida.
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
DE60133028D1 (de) Mikrogranulat auf wirkstoffbasis und verfahren zu seiner herstellung
ES2060293T3 (es) Nueva sustancia antiulcerosa.
FI101855B1 (fi) Menetelmä asetatsolamidia jatkuvasti vapauttavan asetatsolamidivalmisteen valmistamiseksi
JPS5215819A (en) Gramineae weeds controlling agent